



## ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

November 6, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 6, 2018-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

- **Jefferies London Healthcare Conference**  
**November 14, 2018 at 9:40 am ET/2:40 pm GMT**
- **Evercore ISI HealthConX**  
**November 27, 2018 at 8:45 am ET**
- **30th Annual Piper Jaffray Healthcare Conference**  
**November 28, 2018 at 11:30 am ET**

A webcast of each presentation will be accessible live through the "Investors" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay will be available in the same location for approximately two weeks.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now." Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FR $\alpha$ )-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181106005288/en/>

Source: ImmunoGen, Inc.

### INVESTOR RELATIONS CONTACT

ImmunoGen, Inc.

Sarah Kiely, 781-895-0600

[sarah.kiely@immunogen.com](mailto:sarah.kiely@immunogen.com)

or

THRUST Strategic Communications

Chelcie Lister, 910-777-3049

[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)

or

### MEDIA CONTACT

ImmunoGen, Inc.

Courtney O'Konek, 781-895-0600

[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

or

FTI Consulting

Robert Stanislaro, 212-850-5657

[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)